Navigation Links
Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies (APSS) in Minneapolis, Minnesota. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APSS meeting today includes the following:

"Safety and Tolerability in Early Phase I Studies of NG2-73, a Novel GABA(A) Sleep Agent"

NG2-73 is a GABA(A) receptor partial agonist which is alpha-3 subunit preferring. In vivo animal experiments suggest that NG2-73 will be a potent sedative hypnotic and may have an improved side effect profile compared to zolpidem, with respect to ethanol interaction and learning and memory at equipotent hypnotic doses.

The first-in-human studies included a single ascending dose and a five day multiple dose study in healthy subjects. The single ascending dose study started at 0.1 mg of NG2-73 and was planned to ascend to 100 mg of NG2-73 as a powder in a bottle formulation. The multiple ascending dose study was designed to test five days of once per day administration of 5, 10 and 20 mg tablets of NG2-73.

In the single ascending dose study, 48 subjects were enrolled (38 male and 10 female); all 48 subjects completed the study. Doses administered ranged from 0.1 to 60 mg. The 60 mg dose proved to be the maximum tolerated dose, as defined by the depth of sedation. The time to maximum concentration (Tmax) ranged from 0.33 to 3 hours and the half-life (T1/2) was 1.1 to 1.4 hours for all dosage groups. NG2-73 exhibited linear increases in maximum concentration (Cmax) and area under-the-curve (AUC, 0-inf) with increasing doses.

In the multiple ascending dose study, 32 subjec ts were enrolled (20 male and 12 female). Repeated daily dosing of NG2-73 did not result in accumulation and NG2-73 exhibited linear pharmacokinetics. The ability of NG2-73 to produce drowsiness and sleepiness was confirmed by the sedation assessment scores on the Stanford Sleepiness Scale and Visual Analog Scale in the multiple ascending dose study. In both studies the safety and tolerability of the compound were confirmed by the absence of serious adverse events, clinically significant laboratory findings, oxygen saturation level alterations, and electrocardiogram (ECG) abnormalities.

In these studies, NG2-73 was shown to be a novel sedative hypnotic which exhibited linear pharmacokinetics and was well tolerated up to 60 mg. This dosage is estimated to be 10- to 20-times the anticipated therapeutic dose.

About Neurogen

Neurogen Corporation is a drug discovery and development company focusing on small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, obesity, pain, Parkinson's disease, restless legs syndrome (RLS), and depression. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise.

Neurogen Safe Harbor Statement

The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws, which involve risks and uncertainties as detailed from time to time in Neurogen's SEC filings, including its most recent 10-K. Such forward-looking statements relate to activities, events or developments that Neurogen believes, expects or anticipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timin g and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen's ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen's management as of the date of this release and Neurogen disclaims any intent and does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required under applic able law.

Contact

Neurogen Corp.
Elaine Grimsell Dodge, 203-315-4615
edodge@nrgn.com


'"/>




Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 ... Market Research, titled, "Radiology Information System Market by Type, Component, ... Forecast, 2014-2022," the radiology information system market was valued at ... million by 2022, growing at a CAGR of 5.9% from ... over three-fifths share of the total market in 2015. ...
(Date:2/22/2017)... 22, 2017  Based on its recent analysis ... Sullivan recognizes SnooZeal, Inc. with the 2017 European ... innovative product that intelligently addresses the root causes ... through the clinically proven continuous transmucosal electrical stimulation ... is one of the most accessible anti-snoring products ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... The SeniorCare Investor will host an important webinar— Seniors ... 2017, at 1:00 PM ET. A recording of the webinar will also be made ... , If you want to find out what really happened in the seniors housing ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a ... PTSD. , Established in 1977, our organization was at the forefront in working ... to civilian life were evident and served as the catalyst for the establishing ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to ... Multi-Cook Oven offers up to four ovens in one. Control temperature, fan speed ... unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton celebrated ... Oklahoma, on Feb. 21. , The celebration began with a ribbon cutting event ... the construction team and tribal leadership. , Choctaw Nation Durant Regional Medical ...
(Date:2/21/2017)... Angeles, CA (PRWEB) , ... February 21, 2017 , ... ... the United States according to the American Society of Plastic Surgeons. Some patients want ... address the functionality of their nose and improve their breathing ability. The team at ...
Breaking Medicine News(10 mins):